Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dell Technologies Inc (DELL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dell Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Dell Technologies Inc trades at $429.25 (market cap $281.05B). The key difference: Dell Technologies Inc is far larger — about 7× Alnylam Pharmaceuticals, Inc.'s market cap, and Dell Technologies Inc pays a 0.58% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DELL | |
|---|---|---|
Market Cap | $39.89B | $281.05B |
Sector | Health | Technology |
52-Week High | $491.22 | $466.02 |
52-Week Low | $278.09 | $111.10 |
Enterprise Value | $38.15B | $300.64B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Dell Technologies stock trades at $435.05, down 3.37% over the past day, but maintains a bullish technical outlook with strong support near $436. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $4.86 significantly exceeding the $2.96 forecast. Revenue for 2025 reached $95.57 billion with a net income margin of 6.28%, showing improved profitability. Recent news highlights include positive analyst coverage and political endorsements driving investor interest.
The outlook for Dell remains positive with analyst consensus pointing to 12% upside to the $487.06 price target. Key opportunities include AI server demand growth and expanding profit margins, while risks involve PC industry headwinds and competitive pressures. The stock's current valuation at 34.66 P/E requires continued earnings growth to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →
